Dynex Capital reports an 11.5% negative Q3 2026 economic return, with book value falling to $10.91 per share and its mortgage ...
Merck agrees to acquire Silence Therapeutics for $20 per ADS in a $1.3 billion equity deal, adding Divesiran to its rare disease pipeline.
Cytokinetics secures Health Canada approval for MYQORZO after Phase 3 results showed improved exercise capacity in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results